Sutro Biopharma (STRO) Share-based Compensation (2017 - 2025)

Sutro Biopharma has disclosed Share-based Compensation across 9 years of filings, most recently posting $1.7 million for Q4 2025.

• Share-based Compensation for Q4 2025 came in at $1.7 million, down 72.02% year-over-year; the trailing twelve-month figure through Dec 2025 was $14.0 million (down 43.26% YoY), and the FY2025 annual result was $14.0 million, down 43.26% from the prior year.
• Share-based Compensation came in at $1.7 million for Q4 2025 at Sutro Biopharma, up from $1.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $7.0 million in Q1 2022 to a low of $1.6 million in Q3 2025.
• The 5-year median for Share-based Compensation is $6.0 million (2023), against an average of $5.7 million.
• Across the five-year window, Share-based Compensation surged 123.1% in 2021 and plunged 76.29% in 2025, its largest moves.
• Sutro Biopharma's Share-based Compensation stood at $6.9 million in 2021, then dropped by 15.03% to $5.9 million in 2022, then increased by 6.34% to $6.2 million in 2023, then dropped by 4.95% to $5.9 million in 2024, then sank by 72.02% to $1.7 million in 2025.
• The last three Share-based Compensation figures came in at $1.7 million (Q4 2025), $1.6 million (Q3 2025), and $5.3 million (Q2 2025), per Business Quant data.